Nicola Fenwick

Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial

Bernadette Brennan, Laura Kirton, Perrine Marec‐Bérard et al. · The Lancet · 2022 · 125 citations · Full text

Medicine, Oncology, Pharmacology +8

Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial

Helena Earl, Anne-Laure Vallier, Louise Hiller et al. · The Lancet Oncology · 2013 · 119 citations · Full text

Medicine, Oncology, Pharmacology +17

International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours – EURO EWING 2012 Protocol

Jennifer Anderton, V. V. Moroz, Perrine Marec‐Bérard et al. · Trials · 2020 · 113 citations · Full text

Medicine, Oncology, Surgical Oncology +8

Results of the second interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES).

Martin G. McCabe, Laura Kirton, Maria Khan et al. · Journal of Clinical Oncology · 2020 · 45 citations · Full text

Medicine, Oncology, Cancer Drug Toxicity Management +14

Results of the first interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma.

Martin G. McCabe, V. V. Moroz, Maria Khan et al. · Journal of Clinical Oncology · 2019 · 42 citations · Full text

Medicine, Oncology, Cancer Drug Toxicity Management +14